Revisiting Combination Chemotherapy as a Single Modality Palliative Therapy for Advanced Anaplastic Thyroid Carcinoma—a Single Institution Experience
Tóm tắt
Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with dismal outcome especially in metastatic setting. Consensus for ideal treatment of advanced and metastatic ATC remains elusive. This study aimed to analyze the impact of palliative chemotherapy versus supportive care on overall survival in patients with metastatic anaplastic thyroid carcinoma. Patients diagnosed with ATC between the period January 2018 and December 2019 were prospectively followed. The patients opting for palliative chemotherapy received 3 weekly Paclitaxel (175 mg/m2) and Carboplatin (AUC-5). Out of the 31 patients diagnosed with ATC, clinicopathological profile of 29 patients was analyzed (2 patients who underwent upfront surgical resection with curative intent were excluded), out of which 20 patients were included in the survival analysis. The median age of presentation was 55.8 years with male:female ratio 1.9:1. Seventeen out of the total 29 patients presented with anaplastic transformation in long-standing goiter. Nineteen out of 20 (95%) patients presented with distant metastasis with lungs being the most common site. Nodal metastasis was present in all patients. Invasion of the strap muscles (90%) and trachea (80%) was the most common peri-thyroidal tissue invasion followed by invasion of the esophagus (40%), internal jugular vein (30%), and carotid artery (5%). Twelve out of the 20 patients opted for palliative chemotherapy. Overall, median survival from the time of diagnosis was 2.6 months, with median survival in patients receiving chemotherapy 3.1 months and those opting for supportive care 1.6 months (p=0.004). Out of all the factors analyzed, male sex (HR 6.521, 95% CI 1.143–37.206, p value 0.03) and vascular invasion (HR 0.066, 95% CI 0.009–0.499, p value 0.008) were poor prognostic indicators. Palliative chemotherapy showed increased survival benefit in patients with metastatic ATC. Male sex and vascular invasion were found to be significant factors associated with poor outcomes on Cox regression analysis.
Tài liệu tham khảo
Sun XS, Sun SR, Guevara N et al (2013) Chemo radiation in anaplastic thyroid carcinomas. Crit Rev Oncol/ Haematol 86(3):290–301
Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK (2021 Mar) 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 31(3):337–386
Chen J, Tward JD, Shrieve DC, Hitchcock YJ (2008) Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma. Am J Clin Oncol 31(5):460–464
Sharifi A, Shojaeifard A, Soroush A, Jafari M, Abdehgah AG, Mahmoudzade H (2016) Predictors of regional lymph node recurrence after initial thyroidectomy in patients with thyroid cancer. J Thyroid Rese 2016: 4127278
Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9):2155–2160
Higashiyama T, Ito Y, Hirokawa M et al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7–14
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A (2001) Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 25:617–22
Kebebew E, Greenspan FS, Clark OH, Woeber KA (2005) McMillan A Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. . Cancer. 103(7):1330
Pradhan R, Agarwal A, Lal P et al (2018) Clinico-pathological profile of anaplastic thyroid carcinoma in an endemic goiter area. Indian J Endocrinol Metab. 22(6):793–797. https://doi.org/10.4103/ijem.IJEM_264_18
Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M et al (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 86:1848–53
Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J et al (2000) Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer. 89:202–17
Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC (2011) Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011:542358
Giuffrida D, Gharib H (2000) Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol. 11:1083–9
Lehnert M (1996) Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 32(6):912–920
Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest. 10(3):303–310
Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 10(7):587–594
Xia Q, Wang W, Xu J, Chen X, Zhong Z, Sun C (2018) Evidence from an updated meta-analysis of the prognostic impacts of postoperative radiotherapy and chemotherapy in patients with anaplastic thyroid carcinoma. Onco Targets Ther. 11:2251–2257
Sosa JA, Elisei R, Jarzab B, et al (2010) Randomized phase 2/3 trial of a tunor vascular disrupting agent, fosbertubulin (CA4P), with carboplatin(C), and paclitaxel(P) in anaplastic thyroid cancer(ATC): interim safety and efficacy results of the FACT trial. Milan, Italy
Koussis H, Scola A, Tonello S et al (2006) Multimodality therapeutic approach in anaplastic thyroid cancer (ATC): study of 56 patients. J Clin Oncol. 24(18S, supplement) ASCO Annual Meeting Proceedings Part I. Vol. 24
Busnardo B, Daniele O, Pelizzo MR et al (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Investig. 23(11):755–761
Smallridge RC, Copland JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22:486–497